# Bisantrene for Relapsed /Refractory AML

> **NCT03820908** · PHASE2 · COMPLETED · sponsor: **Sheba Medical Center** · enrollment: 10 (actual)

## Conditions studied

- Acute Myelogenous Leukemia
- Allogeneic Stem Cell Transplantation

## Interventions

- **DRUG:** Bisantrene

## Key facts

- **NCT ID:** NCT03820908
- **Lead sponsor:** Sheba Medical Center
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-07-18
- **Primary completion:** 2020-05-19
- **Final completion:** 2020-07-22
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2020-08-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03820908

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03820908, "Bisantrene for Relapsed /Refractory AML". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03820908. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*